標(biāo)題: Titlebook: Cancer Immunology; Bench to Bedside Imm Nima Rezaei Book 20151st edition Springer-Verlag Berlin Heidelberg 2015 Cancer immunology.Cancer im [打印本頁] 作者: Coarse 時(shí)間: 2025-3-21 16:16
書目名稱Cancer Immunology影響因子(影響力)
書目名稱Cancer Immunology影響因子(影響力)學(xué)科排名
書目名稱Cancer Immunology網(wǎng)絡(luò)公開度
書目名稱Cancer Immunology網(wǎng)絡(luò)公開度學(xué)科排名
書目名稱Cancer Immunology被引頻次
書目名稱Cancer Immunology被引頻次學(xué)科排名
書目名稱Cancer Immunology年度引用
書目名稱Cancer Immunology年度引用學(xué)科排名
書目名稱Cancer Immunology讀者反饋
書目名稱Cancer Immunology讀者反饋學(xué)科排名
作者: 最初 時(shí)間: 2025-3-21 20:20
Novel Strategy of Cancer Immunotherapy: Spiraling Up,tanding mechanisms of innate and adaptive immunity are the basis for development and improvement of immunotherapy approaches. Despite the theoretical rationale and experimental basis of antitumor cytotoxicity of induced lymphocytes, adoptive immunotherapy with lymphokine-activated killer cells desig作者: 不確定 時(shí)間: 2025-3-22 02:12 作者: HAVOC 時(shí)間: 2025-3-22 04:59
Tumor Antigen and Epitope Identification for Preclinical and Clinical Evaluation,mune memory. Targeting major histocompatibility complex (MHC) class I and class II epitopes and multiple tumor antigens has met with some clinical success, which is advantageous over single epitope vaccine strategies. Moreover, cancer immunotherapy and peptide therapeutics especially have demonstrat作者: connoisseur 時(shí)間: 2025-3-22 11:49
Strategies to Target Tumor Immunosuppression,rate chapters of this book, these strategies are being reviewed and discussed..An alternative option is to (also) target intratumoral immune escape mechanisms in order to enhance intratumoral antitumor responses. Based on their overall target aim, these strategies can be divided into two main catego作者: VEIL 時(shí)間: 2025-3-22 16:56 作者: VEIL 時(shí)間: 2025-3-22 18:05
Gene Therapy and Virus-Based Cancer Vaccines,ver, the use of gene therapy has been limited by the inability to deliver a therapeutic gene to every cell in the tumor and by the heterogeneity in the enabling mutations found both between and within tumors. However, recent advances in the design of both viral (including non-replicating and oncolyt作者: exostosis 時(shí)間: 2025-3-23 01:09
Immunologic Approaches to Targeting Cancer Stem Cells,ey are responsible for local tumor recurrence and distant metastasis. The inability to target cancer stem cells with current immune approaches may contribute to treatment failure. Novel immunotherapeutic strategies which specifically target cancer-initiating cells may improve their efficacy. In the 作者: 能得到 時(shí)間: 2025-3-23 04:55 作者: Spangle 時(shí)間: 2025-3-23 05:46 作者: 加強(qiáng)防衛(wèi) 時(shí)間: 2025-3-23 13:32
T Cell Immunotherapy: From Synthetic Biology to Clinical Practice, their ability to alter the tumor microenvironment. Polyclonal T cell populations, T cell clones, and T cells engineered to express chimeric antigen receptors (CARs) have all been expanded in various ways outside the body and then reintroduced for therapeutic effect. From naturally occurring T cell 作者: 直言不諱 時(shí)間: 2025-3-23 16:59 作者: 寵愛 時(shí)間: 2025-3-23 21:12
Adoptive T-Cell Therapy: Optimizing Chemokine Receptor-Mediated Homing of T Cells in Cancer Immunotreat majority of patients. During the past few decades, several strategies for enhancing the efficacy of adoptive T-cell therapy have been developed and introduced into the clinic. These include different maneuvers such as ex vivo expansion of autologous lymphocytes isolated from tumor, manipulating作者: 小故事 時(shí)間: 2025-3-23 23:11 作者: 的是兄弟 時(shí)間: 2025-3-24 04:25 作者: jealousy 時(shí)間: 2025-3-24 06:49 作者: Water-Brash 時(shí)間: 2025-3-24 14:02
Recent Advances in the Use of NK Cells Against Cancer,or cells, as well as how tumors try to subvert this attack, has led to many new ideas about how to make NK cell immunotherapy more effective. Advances in both technology and methodology have made it more of a reality to generate large numbers of NK cells to utilize in either autologous or allogeneic作者: concentrate 時(shí)間: 2025-3-24 15:39 作者: 騎師 時(shí)間: 2025-3-24 22:18
H. Kamesaki,S. Fukuhara,H. Uchino,T. Nosakas immunogenic than pathogens, the immune system is capable of recognizing and eliminating tumor cells. However, tumors frequently interfere with the development and function of immune responses. Thus, the challenge for cancer immunotherapy is to apply advances in cellular and molecular immunology an作者: SLING 時(shí)間: 2025-3-24 23:38
Ger J. van der Vusse,Robert S. Renemantanding mechanisms of innate and adaptive immunity are the basis for development and improvement of immunotherapy approaches. Despite the theoretical rationale and experimental basis of antitumor cytotoxicity of induced lymphocytes, adoptive immunotherapy with lymphokine-activated killer cells desig作者: lymphoma 時(shí)間: 2025-3-25 03:30
https://doi.org/10.1007/978-4-431-68219-6ity of tumor is high. One of the principal causes of this situation is the lack of clinical prognostic biomarkers, useful for the diagnostic and therapeutic monitoring and for the definition of personalized treatments that could lead to improvement in the therapeutic success rate..In the neoplastic 作者: flavonoids 時(shí)間: 2025-3-25 09:24
https://doi.org/10.1007/978-4-431-68219-6mune memory. Targeting major histocompatibility complex (MHC) class I and class II epitopes and multiple tumor antigens has met with some clinical success, which is advantageous over single epitope vaccine strategies. Moreover, cancer immunotherapy and peptide therapeutics especially have demonstrat作者: 摘要 時(shí)間: 2025-3-25 12:35 作者: 茁壯成長 時(shí)間: 2025-3-25 15:51 作者: DUST 時(shí)間: 2025-3-25 20:47 作者: 敏捷 時(shí)間: 2025-3-26 03:58 作者: 聯(lián)想 時(shí)間: 2025-3-26 08:03
https://doi.org/10.1007/978-1-4419-1676-1 for hematologic malignancies and, more recently, has shown efficacy for the treatment of solid tumors. Destruction of hematopoietic cells through myeloablative or non-myeloablative “conditioning” serves to eliminate or reduce numbers of malignant cells, create “space” in the hematopoietic compartme作者: Airtight 時(shí)間: 2025-3-26 08:55 作者: Flounder 時(shí)間: 2025-3-26 12:45 作者: Nomogram 時(shí)間: 2025-3-26 16:58
Optical medical diagnostics and imaging,hem attractive targets for cancer immunotherapy, namely, their MHC-unrestricted recognition of tumors, potent cytotoxicity, and abundant production of interferon-γ (IFN-γ) and tumor necrosis factor (TNF). Moreover, seminal work with mice genetically deficient for γδ T cells has clearly shown they co作者: GLIDE 時(shí)間: 2025-3-26 21:54 作者: 名詞 時(shí)間: 2025-3-27 02:49 作者: 細(xì)頸瓶 時(shí)間: 2025-3-27 09:20
Michel Campillo,Ludovic Margerin,Keiiti Akiring methods has made it possible for investigators to develop antibody structures with improved antitumor effects. The development of efficacious therapeutic mAbs entails gaining in-depth knowledge about factors including antibody structure and function, the properties of an ideal tumor antigen, th作者: LEERY 時(shí)間: 2025-3-27 12:39 作者: Exaggerate 時(shí)間: 2025-3-27 14:17
IRAS observations of the Magellanic clouds,or cells, as well as how tumors try to subvert this attack, has led to many new ideas about how to make NK cell immunotherapy more effective. Advances in both technology and methodology have made it more of a reality to generate large numbers of NK cells to utilize in either autologous or allogeneic作者: 誘拐 時(shí)間: 2025-3-27 21:34 作者: malapropism 時(shí)間: 2025-3-27 22:59
Nima RezaeiOffers an up-to-date review of cancer immunology in animal models and human cancers.Provides a bench to bedside approach to the immunology of cancers, with a focus on clinical aspects.Describes in dep作者: Autobiography 時(shí)間: 2025-3-28 05:59 作者: 頭腦冷靜 時(shí)間: 2025-3-28 10:17
https://doi.org/10.1007/978-3-662-44946-2Cancer immunology; Cancer immunotherapy; Cancer stem cells; Radioimmunotherapy; Translational medicine作者: Externalize 時(shí)間: 2025-3-28 13:51 作者: overrule 時(shí)間: 2025-3-28 16:55
f cancers, with a focus on clinical aspects.Describes in depThis translational book describes in detail the clinical application of novel approaches in cancer immunotherapy with the aim of educating clinicians in the implications of the most recent research and new developments in the field. The sco作者: Anhydrous 時(shí)間: 2025-3-28 20:50 作者: Dna262 時(shí)間: 2025-3-29 01:23 作者: 燒瓶 時(shí)間: 2025-3-29 05:30 作者: 激勵(lì) 時(shí)間: 2025-3-29 10:44
Monoclonal Antibodies for Cancer Immunotherapy,rapeutic mAbs entails gaining in-depth knowledge about factors including antibody structure and function, the properties of an ideal tumor antigen, the advantages of employing combinational therapies, and the limitations of antibody-based modalities. This chapter concentrates on mAbs as versatile platforms for cancer immunotherapy.作者: Ancillary 時(shí)間: 2025-3-29 12:18
Book 20151st editionin the implications of the most recent research and new developments in the field. The scope is broad, encompassing, for example, prognostic biomarkers for personalized cancer treatment, strategies for targeting tumor immunosuppression, gene therapy, virus-based vaccines, targeting of cancer stem ce作者: 蚊帳 時(shí)間: 2025-3-29 19:07
Ger J. van der Vusse,Robert S. Renemantherapeutic options to a broad range of malignancies. This chapter will review the rationale for targeting immune checkpoints, the pathways of particular interest, and the research being conducted to bring checkpoint blockade to clinical use.作者: AMEND 時(shí)間: 2025-3-29 23:34 作者: HALL 時(shí)間: 2025-3-29 23:58
Overcoming Cancer Tolerance with Immune Checkpoint Blockade,therapeutic options to a broad range of malignancies. This chapter will review the rationale for targeting immune checkpoints, the pathways of particular interest, and the research being conducted to bring checkpoint blockade to clinical use.作者: Infusion 時(shí)間: 2025-3-30 05:42
Toll-Like Receptor Pathway and its Targeting in Treatment of Cancers,e TLR function varies according to the cancer type and the TLRs expressed, their signaling pathway should either be triggered or targeted to control cancer progression. Hence, more investigations are required to discover proper therapeutic approaches for cancer.作者: 縮減了 時(shí)間: 2025-3-30 09:10
Ger J. van der Vusse,Robert S. Renemanffectiveness of DC vaccines is relatively low. Review of the numerous research data on cell-based technologies including the authors’ results suggests a new comprehensive concept of the most effective implication of antitumor immunotherapy.作者: 助記 時(shí)間: 2025-3-30 15:36
https://doi.org/10.1007/978-1-4419-1676-1immune cells. Discussed in this chapter are treatments used to deplete hematopoietic cells and/or induce lymphodepletion, how these treatments are used as preconditioning for autologous and allogeneic HSCT, and how lymphodepletion augments an antitumor immune response during hematopoietic cell reconstitution.作者: obeisance 時(shí)間: 2025-3-30 17:49
Dirk Feldmeyer,Joachim H.R. Lübkemolecules not encoded by the genome, an example of synthetic biology, T cell immunotherapy is an exemplary model of the translation of basic concepts developed at the bench to cutting-edge therapeutic options for patients with advanced disease.作者: Benign 時(shí)間: 2025-3-31 00:38
Novel Strategy of Cancer Immunotherapy: Spiraling Up,ffectiveness of DC vaccines is relatively low. Review of the numerous research data on cell-based technologies including the authors’ results suggests a new comprehensive concept of the most effective implication of antitumor immunotherapy.作者: indenture 時(shí)間: 2025-3-31 02:28
Hematopoietic Stem Cell Transplantation and Lymphodepletion for the Treatment of Cancer,immune cells. Discussed in this chapter are treatments used to deplete hematopoietic cells and/or induce lymphodepletion, how these treatments are used as preconditioning for autologous and allogeneic HSCT, and how lymphodepletion augments an antitumor immune response during hematopoietic cell reconstitution.作者: peritonitis 時(shí)間: 2025-3-31 09:01 作者: 厭食癥 時(shí)間: 2025-3-31 10:23 作者: linguistics 時(shí)間: 2025-3-31 13:37 作者: constitute 時(shí)間: 2025-3-31 21:23
Ger J. van der Vusse,Robert S. Renemanher by overcoming tumor-induced tolerance or by overriding the immunosuppressive mechanisms imposed during tumor development, are depletion or functional inhibition of immunosuppressive populations, blockade of negative regulatory factors, and blockade of tumor growth factor-beta (TGF-β)-induced sig作者: FER 時(shí)間: 2025-3-31 23:25 作者: 薄荷醇 時(shí)間: 2025-4-1 02:13
Esther T. Stoeckli,Vera Niederkoflerenographs have also been described. Recently, cancer stem cell vaccine has been shown to be capable of inducing protection against tumors in immunocompetent mice. In these models the mechanisms involved specific targeting of cancer stem cells by cancer stem cell-primed T cells and antibodies. Finall作者: 加劇 時(shí)間: 2025-4-1 07:14
Moritz Helmstaedter,Dirk Feldmeyerarly limits its potential efficacy. In this context, protocols combining chemotherapy and immunotherapy with cytokines demonstrated potential for therapeutic synergy. For example, cyclophosphamide, gemcitabine, paclitaxel, and doxorubicin have been used for this purpose. Moreover, new studies indica作者: Cardiac-Output 時(shí)間: 2025-4-1 12:35
Optical medical diagnostics and imaging,itations will be reviewed. Finally, as to stimulate more research on the mechanisms that govern the interactions between γδ T cells and tumors, this chapter will end by discussing future perspectives in γδ T-cell-based cancer immunotherapy.作者: 廣口瓶 時(shí)間: 2025-4-1 15:36 作者: 1分開 時(shí)間: 2025-4-1 21:56
